<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A768E7D-C2F9-43A3-A00E-2F65D673ED46"><gtr:id>4A768E7D-C2F9-43A3-A00E-2F65D673ED46</gtr:id><gtr:name>Sareum Limited</gtr:name><gtr:address><gtr:postCode>CB22 3FX</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A768E7D-C2F9-43A3-A00E-2F65D673ED46" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>4A768E7D-C2F9-43A3-A00E-2F65D673ED46</gtr:id><gtr:name>Sareum Limited</gtr:name><gtr:address><gtr:postCode>CB22 3FX</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>139755.0</gtr:offerGrant><gtr:projectCost>199650.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/26D69601-3B91-4270-9F31-C8F9E1D88E2B"><gtr:id>26D69601-3B91-4270-9F31-C8F9E1D88E2B</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Reader</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=132038"><gtr:id>35C75F5A-4F67-4C9F-982D-70739FD121E5</gtr:id><gtr:title>Studies to validate novel inhibitors of TYK2 kinase as anti-cancer therapeutics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>132038</gtr:grantReference><gtr:abstractText>The enzyme TYK2 has been shown to be a key therapeutic target in a rare type of leukaemia, T-ALL, which predominantly affects young adults. Sareum has discovered a novel series of selective inhibitors of TYK2, and have shown that they can prevent T-ALL cells from proliferating by causing programmed cell death. The aim of this feasibility study is to assess more compounds against additional T-ALL cell lines and to develop a broader understanding of the biology connecting T-ALL and TYK2. If the project is successful it would warrant further investment in a full lead optimisation programme to develop candidate molecules for clinical trials in patients.</gtr:abstractText><gtr:fund><gtr:end>2016-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>139755</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">132038</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>